Altimmune Announces Financial Results for the Year Ended December 31, 2017 and Provides Corporate Update

Pharmaceutical Investing

Altimmune (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced financial results for the year ended December 31, 2017. As quoted in the press release: “We have had a very data-rich few weeks with results being reported from our NasoVAX, HepTcell, and SparVax-L programs and moving forward on enrollment in our Phase 1 trial of NasoShield,” said …

Altimmune (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced financial results for the year ended December 31, 2017.

As quoted in the press release:

“We have had a very data-rich few weeks with results being reported from our NasoVAX, HepTcell, and SparVax-L programs and moving forward on enrollment in our Phase 1 trial of NasoShield,” said William J. Enright, Chief Executive Officer of Altimmune. “We are very excited by the positive results from our NasoVAX trial and look forward to continuing to advance that program. NasoVAX is a very different type of flu vaccine that has tremendous potential as an effective, easy-to-use vaccine that potentially provides better protection than current vaccines. We are also excited by the results on our SparVax-L trial and look forward to moving that program forward once we secure additional government funding. We continue to evaluate our HepTcell results will update investors on our next steps as we better understand those results.”

Click here to read the full press release.

enrollment financial results phase 1 trial vaccine vaccines Pharmaceutical Investing